… -line treatment of previously untreated patients with Multiple Myeloma (MM) … meta-analysis
(NMA) till date have ignored the equally important safety outcome. In this systematic review, …

… OS (39.3 v 32.7 months) reported in a meta-analysis of six phase III trials of MP plus thalidomide
(MPT) versus MP. The HR for OS in this meta-analysis was 0.83 (95% CI, 0.73 to 0.94; P …

… multiple myeloma was 53.9%, an increase from 34.6% in 1998 [4]. This surge in survival
correlates with the introduction of novel agents such as bortezomib … randomized controlled trials […

… In this meta-analysis of all randomized trials comparing early … SCT”) in patients with newly
diagnosed multiple myeloma, a … randomized clinical trials that reported outcomes of patients (…

… was conducted to find randomized controlled trials (RCTs) that included patients with MM
that … in many clinical studies. The purpose of this current meta-analysis was to systematically …

… treatment of multiple myeloma (MM) and non-Hodgkin lymphoma[6]. It has also shown promising
… However, only six randomized controlled trials included in our study, we thus could not …

… By using the clinical data all from randomized controlled studies, … With the advent of thalidomide
and bortezomib ending the … Preferred Reporting Items for Systematic Reviews and Meta-…

… the reporting of systematic reviews and meta-analysis were … diagnosed multiple myeloma: a
clinical trial coordinated by the … induction therapy in previously untreated multiple myeloma. J …

… , initial Phase I/II and confirmatory Phase III clinical trials were … According to a recent
systematic review an indirect … treatment with bortezomib and thalidomide versus bortezomib and …

… of 18 randomized clinical trials (enrolling 7730 patients) that … in MM were included in the
present meta-analysis ( 19–36 ). … this study in our meta-analysis because both bortezomib and …